Sherry Aulin - Sep 2, 2022 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Chief Financial Officer
Signature
/s/ Cassandra Robinson, Attorney-in-fact
Stock symbol
XENE
Transactions as of
Sep 2, 2022
Transactions value $
-$607,708
Form type
4
Date filed
9/7/2022, 04:26 PM
Previous filing
Mar 14, 2022
Next filing
Mar 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $85K +9K $9.44* 9K Sep 2, 2022 Direct
transaction XENE Common Shares Options Exercise $240 +32 +0.36% $7.49* 9.03K Sep 2, 2022 Direct
transaction XENE Common Shares Options Exercise $6.83K +813 +9% $8.40* 9.85K Sep 2, 2022 Direct
transaction XENE Common Shares Options Exercise $7.11K +2.29K +23.28% $3.10* 12.1K Sep 2, 2022 Direct
transaction XENE Common Shares Options Exercise $30.9K +6.51K +53.65% $4.75* 18.6K Sep 2, 2022 Direct
transaction XENE Common Shares Tax liability -$130K -3.29K -17.66% $39.53 15.4K Sep 2, 2022 Direct F1
transaction XENE Common Shares Sale -$608K -15.4K -100% $39.57 0 Sep 2, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -9K -100% $0.00* 0 Sep 2, 2022 Common Shares 9K $9.44 Direct F3
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -32 -100% $0.00* 0 Sep 2, 2022 Common Shares 32 $7.49 Direct F3
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -813 -100% $0.00* 0 Sep 2, 2022 Common Shares 813 $8.40 Direct F3
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -2.29K -100% $0.00* 0 Sep 2, 2022 Common Shares 2.29K $3.10 Direct F3
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -6.51K -100% $0.00* 0 Sep 2, 2022 Common Shares 6.51K $4.75 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the closing price of the Company's common shares on September 1, 2022 for purposes of net settlement calculations.
F2 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The shares subject to the option are fully vested and exercisable.